年轻女性的子宫内膜癌:突尼斯队列的见解
Mouna Kouira1, Ekram Guerbej1, Riadh Ncibi1
1Department of Obstetrics and Gynecology, Faculty of Medicine "Ibn El Jazzar" of Sousse/Farhat Hached University Hospital, Sousse, TUN.
Cureus
|November 4, 2025
概括
年轻女性的子宫内膜癌 (EC) 是罕见的,但通常具有良好的结果. 节育治疗是可行的,在突尼斯,常规病理指导预后.
科学领域:
- 妇科 妇科医生 妇科
- 在瘤学瘤学.
- 生殖医学 生殖医学
背景情况:
- 在40岁以下的女性中,子宫内膜癌 (EC) 是罕见的,通常呈现出有利的预后特征.
- 年轻女性的治疗需要平衡生育保护与瘤安全.
- 关于北非的年轻EC患者的数据有限.
研究的目的:
- 分析40岁或以下妇女子宫内膜癌的临床特征,治疗和结局.
- 提供突尼斯中部这个子组的第一个专用数据.
- 评估节育管理的可行性和结果.
主要方法:
- 对于被诊断患有EC的40岁以下妇女 (2010-2022) 的医疗记录的回顾性审查.
- 分析临床,病理,成像和治疗数据.
- 使用Kaplan-Meier和日志等级测试对生存结果进行统计分析.
主要成果:
- 鉴定了24名年轻女性 (占所有EC病例的6.3%),平均年龄为34岁.
- 不孕症 (79.2%) 和肥胖 (58.3%) 是常见的并发症.
- 子宫内膜腺癌是主要的组织学 (66.7%); 33.3%接受了节育治疗.
结论:
- 40岁以下女性的子宫内膜癌不常见,但通常与有利的结果有关.
- 传统的病理因素是这一群体的关键预后决定因素.
- 针对量身定制的管理策略需要对分子分析进行进一步的研究.
相关概念视频
Infertility in Females
3.6K
Female infertility is defined as the inability to conceive after a year of regular, unprotected intercourse and affects about 10–15% of couples worldwide. The primary cause of female infertility is ovulatory disorders, which hinder the release of eggs. These disorders can be classified as hypothalamic amenorrhea, polycystic ovarian syndrome (PCOS), premature ovarian failure, and hyperprolactinemic anovulation disorders.
Endometriosis, a condition characterized by abnormal growth of...
Endometriosis, a condition characterized by abnormal growth of...
3.6K
Cancer Prevention
7.6K
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Some...
7.6K
Cancer Survival Analysis
639
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
639
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
Tumor Progression
7.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.2K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K


